UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO.     | FILING DATE                    | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---------------------|--------------------------------|----------------------|---------------------|------------------|
| 09/787,840          | 07/06/2001                     | Mark Leslie Smythe   | 36677.8             | 8048             |
| 27683<br>HAYNES AND | 7590 08/08/200<br>DBOONE, LLP  | EXAMINER             |                     |                  |
| 901 Main Street     |                                |                      | KAM, CHIH MIN       |                  |
|                     | Suite 3100<br>Dallas, TX 75202 |                      | ART UNIT            | PAPER NUMBER     |
|                     |                                |                      | 1656                |                  |
|                     |                                |                      |                     |                  |
|                     |                                |                      | MAIL DATE           | DELIVERY MODE    |
|                     |                                |                      | 08/08/2008          | PAPER            |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

|   | Application No.   | Applicant(s)   |  |  |
|---|---|--|--|--|
|   | 09/787,840  | SMYTHE ET AL.  |  |  |
| Office Action Summary   | Examiner  | Art Unit   |  |  |
|   | CHIH-MIN KAM  | 1656   |  |  |
| The MAILING DATE of this communication app<br>Period for Reply  | pears on the cover sheet with the c   | orrespondence address  |  |  |
| A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DATE of the strength of the may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  If NO period for reply is specified above, the maximum statutory period varieties to reply within the set or extended period for reply will, by statute any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).   | ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tir vill apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE | N. nely filed the mailing date of this communication. D (35 U.S.C. § 133). |  |  |
| Status  |   |  |  |  |
| Responsive to communication(s) filed on <u>05 M</u> This action is <b>FINAL</b> . 2b) ☐ This     Since this application is in condition for allowar closed in accordance with the practice under E  | action is non-final.  |  |  |  |
| Disposition of Claims   |   |  |  |  |
| 4) ☐ Claim(s) 1-5,7-31,35 and 39-43 is/are pending 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) 1-5,7-16,35,41 and 42 is/are allowed. 6) ☐ Claim(s) 43 is/are rejected. 7) ☐ Claim(s) 17-31,39 and 40 is/are objected to. 8) ☐ Claim(s) are subject to restriction and/o   | wn from consideration.  |  |  |  |
|   |   |  |  |  |
| 9) ☐ The specification is objected to by the Examine 10) ☑ The drawing(s) filed on 22 March 2001 is/are: a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) ☐ The oath or declaration is objected to by the Ex  | a)⊠ accepted or b)⊡ objected to<br>drawing(s) be held in abeyance. Section is required if the drawing(s) is ob  | e 37 CFR 1.85(a).<br>jected to. See 37 CFR 1.121(d).                       |  |  |
| Priority under 35 U.S.C. § 119  |   |  |  |  |
| <ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul> |   |  |  |  |
| Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date  | 4)  Interview Summary Paper No(s)/Mail Di 5)  Notice of Informal F 6)  Other:   | ate  |  |  |

Application/Control Number: 09/787,840 Page 2

Art Unit: 1656

#### **DETAILED ACTION**

## Status of the Claims

1. Claims 1-5, 7-31, 35 and 39-43 are pending.

Applicant's amendment filed May 5, 2008 is acknowledged, and applicants' response has been fully considered. Claims 1, 14, 23 and 41-43 have been amended. Therefore, claims 1-5, 7-31, 35 and 39-43 are examined.

# Withdrawn Claim Objections

2. The previous objection to claim 11 is withdrawn in view of applicants' amendment of the claims, and applicant's response at page 23 in the amendment filed May 5, 2008.

### Withdrawn Claim Rejections - 35 U.S.C. § 112

3. The previous rejection of claims 1-5, 7-10, 12-31, 35 and 39-43 under 35 U.S.C. § 112, second paragraph, is withdrawn in view of applicants' amendment of the claims, and applicant's response at page 22 in the amendment filed May 5, 2008.

# Claim Objections

4. Claims 17-31, 39 and 40 are objected to because the claims recites "linking an auxiliary compound as defined in claim 1", while claim 1 and claims 17-31, 39 and 40 are all method claims. It is more appropriate to change claims 17, 22, 24, 26 and 30 to independent form that recites the auxiliary compound of General Formula II having all the definitions for each functional group in the formula II as shown in claim 1.

#### New Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

Art Unit: 1656

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claim 43 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claim 43 is directed to a method of on-resin cyclization of a peptide or peptidomimetic, comprising at least the steps of using a cyclic aromatic auxiliary compound of the formula  $C_6H_3(CHO)$  (OH)(NO<sub>2</sub>) as a linker linking the alpha-nitrogen of an amino acid residue in the desired peptide or peptidomimetic to a solid support to form a secondary amine; synthesizing a linear peptide or peptidomimetic on a solid support, using standard solid phase peptide synthesis methods; deprotecting the desired amine and carboxylic acid groups; activating the carboxylic acid group to perform cyclization and optionally deprotecting amino acid side chain groups; and/or cleaving the cyclic peptide from the solid support.

In *University of California v. Eli Lilly & Co.*, 43 USPQ2d 1938, the Court of Appeals for the Federal Circuit has held that "A written description of an invention involving a chemical genus, like a description of a chemical species, 'requires a precise definition, such as by structure, formula, [or] chemical name,' of the claimed subject matter sufficient to distinguish it from other materials". As indicated in MPEP § 2163, the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional

Art Unit: 1656

characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show that Applicant was in possession of the claimed genus. In addition, MPEP § 2163 states that a representative number of species means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus.

While the specification discloses using the auxiliary compound of the General Formula II having a covalent linkage to a solid support and the linear peptide can be cyclized on-resin (page 24, line 6 to page 26, line 26), the specification does not disclose using the compound of the formula C<sub>6</sub>H<sub>3</sub>(CHO) (OH)(NO<sub>2</sub>) as a linker linking the alpha-nitrogen of an amino acid residue in the peptide or peptidomimetic to a solid support, and synthesizing a peptidomimetic on a solid support, using standard solid phase peptide synthesis methods. The disclosure of using the compound of the General Formula II as an auxiliary compound to facilitate on-resin cyclization of a peptide in the claimed method does not provide sufficient written description for using the compound of the formula C<sub>6</sub>H<sub>3</sub>(CHO) (OH)(NO<sub>2</sub>) as an auxiliary compound to facilitate on-resin cyclization of a peptide or a peptidomimetic since there is no functional group in the compound of C<sub>6</sub>H<sub>3</sub>(CHO) (OH)(NO<sub>2</sub>) linked to a solid support. Furthermore, the specification does not disclose a peptidomimetic can be synthesized on a solid support using standard solid phase peptide synthesis methods. Without guidance on the method steps of using the compound of the formula C<sub>6</sub>H<sub>3</sub>(CHO) (OH)(NO<sub>2</sub>) as an auxiliary compound to facilitate on-resin cyclization of a peptide or a peptidomimetic, one skilled in the art would not know how the compound of  $C_6H_3(CHO)$  (OH)(NO<sub>2</sub>) is used as an auxiliary compound in the claimed method. The lack of

Application/Control Number: 09/787,840 Page 5

Art Unit: 1656

description of using the compound of C<sub>6</sub>H<sub>3</sub>(CHO) (OH)(NO<sub>2</sub>) as an auxiliary compound to facilitate on-resin cyclization of a peptide or a peptidomimetic, and the lack of representative species as encompassed by the claims, applicants have failed to sufficiently describe the claimed invention, in such full, clear, concise terms that a skilled artisan would not recognize applicants were in possession of the claimed invention.

# New Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claim 43 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 43 is indefinite because of the use of term "using a cyclic aromatic auxiliary compound of the formula C<sub>6</sub>H<sub>3</sub>(CHO) (OH)(NO<sub>2</sub>) as a linker linking the a-nitrogen of an amino acid residue in the desired peptide of peptidomimetic to a solid support...." or "(ii) synthesizing a linear peptide or peptidomimetic on a solid support, using standard solid phase peptide synthesis methods". The term cited renders the claim indefinite, it is not clear how the compound of the formula C<sub>6</sub>H<sub>3</sub>(CHO) (OH)(NO<sub>2</sub>) is used as a linker to link to a solid support since the compound does not have a functional group to link to a solid support; and it is also not clear how a peptidomimetic is synthesized by a standard solid phase peptide synthesis method since the peptidomimetic is not a peptide. It is noted that the citation should be linking alphanitrogen of an amino acid residue in the desired peptide or peptidomimetic to a solid support, not "a-nitrogen" and "of peptidomimetic" in the claim.

Application/Control Number: 09/787,840 Page 6

Art Unit: 1656

Conclusion

7. Claim 43 is rejected; and claims 17-31, 39 and 40 are objected to. It appears that claims

1-5, 7-16, 35, 41 and 42 are free of art.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The

examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Kathleen Bragdon can be reached at 571-272-0931. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Chih-Min Kam/

Primary Examiner, Art Unit 1656

**CMK** 

August 5, 2008